Turkish Journal of Medical Sciences
Volume 31

Number 5

Article 5

1-1-2001

Bcl - 2 Expression in Carcinoma of the Uterine Cervix and its
Relationship with Prognostic Variables
SEMA ZERGEROĞLU
TAYFUN GÜNGÖR
ORHAN S. AKSAKAL
EMEL EBRU PARLAKYİĞİT
OYA GÖKMEN

Follow this and additional works at: https://journals.tubitak.gov.tr/medical
Part of the Medical Sciences Commons

Recommended Citation
ZERGEROĞLU, SEMA; GÜNGÖR, TAYFUN; AKSAKAL, ORHAN S.; PARLAKYİĞİT, EMEL EBRU; and GÖKMEN,
OYA (2001) "Bcl - 2 Expression in Carcinoma of the Uterine Cervix and its Relationship with Prognostic
Variables," Turkish Journal of Medical Sciences: Vol. 31: No. 5, Article 5. Available at:
https://journals.tubitak.gov.tr/medical/vol31/iss5/5

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for
inclusion in Turkish Journal of Medical Sciences by an authorized editor of TÜBİTAK Academic Journals. For more
information, please contact academic.publications@tubitak.gov.tr.

Turk J Med Sci
31 (2001) 401-404
© TÜB‹TAK
1

Sema ZERGERO⁄LU
2
Tayfun GÜNGÖR
2
Orhan S. AKSAKAL
2
Emel Ebru PARLAKY‹⁄‹T
2
Oya GÖKMEN

Bcl – 2 Expression in Carcinoma of the Uterine
Cervix and its Relationship with Prognostic
Variables

Received: December 25, 1998

Abstract: Objective: The aim of this study
was to evaluate the importance of the
apoptotic activity of squamous cell carcinoma
of the cervix and Bcl-2 expression.
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Materials and Methods: Twenty-seven
women with cervical squamous cell
carcinoma, admitted to our unit between
1996 and 1998, were reviewed. Patients
were classified according to staging and
grading systems. Bcl-2 protein material was
investigated by immunohistochemistry
(streptoavidin, biotine, alkaline phosphatase
technique).

Introduction
Cervical carcinomas are significant female genital
tumors. Squamous cell carcinomas are the most frequent
cervical cancers, while adenocarcinoma and other types
are less frequent (1).
There are keratinised and non-keratinised large-cell
and non-keratinised small-cell squamous cell carcinomas.
Stage, grade, invasion depth and differentiation degree
are factors that affect the prognosis (1,2).
Early sexual activity, race, changing partners
frequently, smoking and HPV 16 and 18 are also
significant (1,2).
Bcl-2 is a protooncogene situated in the inner
mitochondrial membrane. It is a 24 kilodalton protein
with 239 amino acids which protects the cells from
apoptosis and is localised on the long arm of the 18th
chromosome (3).
It is found in the endoplasmic reticulum and some
parts of the nuclear membrane (4).
Bcl-2 oncoprotein inhibits programmed cell death.
Some data supports the theory that they control the cell
growth by the redox system (5,6).
We studied the prognostic importance of Bcl-2 protein
as a protooncogene in cervical carcinomas.

Results: After immunohistochemical staining,
12 of the 27 cases stained positively (44%).
There was a correlation between the grade
and staining percentage. We found no
significant relationship with stage and staining
intensity.
Conclusions: Bcl-2 could be used as a marker
for blocking well-programmed cell death in
low grade cases.
Key Words: Cervical carcinoma, genital tract
tumors, Bcl-2

Materials And Methods
Our study group was composed of 27 patients
diagnosed with squamous cell carcinomas in 1996-1998
in Zekai Tahir Burak Women’s Hospital. Three patients
with other types of cervical carcinomas were not
considered (none of the cases in our study had
radiotherapy). Extrafascial hysterectomy was adequate
treatment of stage-one patients, when preservation of
fertility was not desired. In stage II and more advanced
disease, radical surgery (class III hysterectomy) was the
choice of treatment. The reasons for the selection of
radical surgery over radiation include bowel problems,
fibrosis and ovarian function. All patients in stage II and
III were premenopausal.
Materials were fixed in 10% formalin solution and
embedded in paraffin blocks after routine tissue followup processes. Haematoxylen stain was applied to sections
which were prepared from these blocks and evaluated
again.
We considered the cases according to FIGO staging
and grading systems. Sections 4 mm in thickness were
made from the same blocks. The presence of Bcl-2
protein (antibcl-2 124 DAKO) antimouse antibody was
investigated by using streptoavidin, biotine, alkaline
phosphatase technique and immunohistochemical
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methods. Bcl-2 antibody was expressed in cyctoplasma.
Fast red was used as the chromogen. Staining intensity
was evaluated according to the arbitrary grading system
as follows: (+), weak; (++), moderate; (+++), strong
positivity.
The Fisher Exact test and the Chi-Square test were
used for statistical analysis and P< 0.05 was considered
significant.

Results
The youngest patient was 18 and the oldest was 63.
The median age was 40.8, 12 (44%) of the 27 cases
(diagnosed as cervical squamous cell cancer) were stage I,
7 (26%) were stage II, and 8 (30%) were stage III; there
were no stage IV cases.
Nine cases (33%) were grade I (well differentiated),
11 cases (41%) were grade II (moderately differentiated)
and 7 cases (26%) were grade III (poorly differentiated).
After immunohistochemical staining, 12 of the 27 cases
stained positively (44%).
Six of these 12 cases were grade I, 4 were grade II
and 2 were grade III. There is a positive correlation
between the grade and staining percentage. When we
consider the staining intensity, 4 cases were (+++), 3
were (++) and 5 were (+).
Three of the 4 (+++) cases were grade I and 1 of the
(+++) cases were grade III. All 3 of the (++) cases were
grade II.

Three of the 5 (+) cases were grade I, and 2 of them
were grade III.
We found no statistically significant relationship
between the staining intensity and the grade.
Five of the 12 stage I cases, 3 of the 7 stage II cases
and 4 of the 8 stage III cases were positively stained with
Bcl-2.
We found no statistically significant relationship
between the staining intensity and the stage (Chi-square
test). The distribution of the cases according to their
grade, stage, Bcl-2 positivity and staining intensity are
shown in the Table.
We found no relationship between the stage and the
Bcl-2 staining intensity.
Five cases had lymph node metastasis (grade I: 1 case,
grade II: 1 case, grade III: 3 cases).
Ten cases had vascular invasion and 8 cases had
necrosis.
None of the cases with lymph node metastasis stained
positively with Bcl-2 (grade II: 1 case, grade III: 7 cases).
Two cases with vascular invasion (grade III) and 3
cases with necrosis (grade III) stained positively with Bcl2 (Fischer Exact test).

Discussion
Squamous cell carcinomas are the most common
cervical carcinomas. They are studied in 3 different
Table:

Staining intensity
Bcl-2
n

%

Bcl-2+

%

+

++

+++

Grade
I
II
III

9
11
7

33
41
26

6
4
2

50
33
17

3
2

3
-

3
1

Total

27

100

12

100

5

3

4

Stage
I
II
III

12
7
8

44
26
30

5
3
4

42
25
33

Total

27

100

12

100
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The distribution of the cases
according to their grade stage Bcl2 positivity and staining intensity.
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categories (large cell keratinised, non-keratinised and
small cell non keratinised ).
The best prognosis is seen in the large-cell keratinised
type, while the small-cell non-keratinised type has the
worst prognosis (1).
Early sexual activity and multiple sexual partners
increase the cancer incidence (2).
Low socio-economic level, smoking and HPV 16 and
18 are important etiologic factors.
Tumor markers (oncogene, protooncogene, and
suppressor genes) are also studied, together with Iymph
node invasion, stage, vascular invasion, grade, metastasis
and age, which are factors that affect the prognosis.
Bcl-2 is an inhibitor gene for apoptosis (4,5). Bcl-2
was recognised for the first time in Bcl Iymphoma and
non-Hodgkin’s follicular Iymphoma (with +(14-15)
(q32:q31) translocation) in 1984 (6,7).

expressed in 65% of cervix squamous cell carcinomas
while P53 was stained positively in only 10% (10). Our
Bcl-2 positivity was 44%.
Tjalma et al. studied Bcl-2 oncoprotein in in-situ
carcinomas of the cervix and uterine cervical carcinomas.
They supported the idea that Bcl-2 was a strong
prognostic marker in in-situ carcinomas and invasive
carcinomas (11,12).
Kokowa et al. studied Bax protein with the in-situ
hybridisation technique in cervical squamous cell
carcinomas and adenocarcinomas and they found a high
expression for Bax protein and a low expression for Bcl2 (13).
Havima et al. using similar markers (Bax, Bcl-2),
indicated that Bax and Bcl-2 may be good prognostic
markers in post-radiotherapy cervical carcinomas (14).

The Bcl-2 gene family includes a variety of genes: aCell death suppressor Bcl-2; b-Cell death promotors Bax,
Bcl-xs, Bak, Bad (5).

Pillai et al. studied Bcl-2 and P53 positively
immunohistochemically in post-radiotherapy cervical
carcinomas. They found that reduced Bcl-2 expressions
correlated positively with DNA damage while there was
no correlation with P53 (15). In our study, we found
significantly reduced Bcl-2 rates related with increased
grade. This may help to explain our result.

Bcl-2 expression is higher in foetal tissues than in
adults. It is thought that it may be related to
morphogenesis (7,8).

Crafford et al. showed that Bcl-2, Mcl-11, Bax and
P53 were not good markers in cervical squamous cell
carcinomas (16).

There are 3 main groups of Bcl-2 in adult tissues (7):

Waggoner et al. studied Bcl-2 and P53 expression in
clear-cell adenocarcinomas of the cervix. P53 expression
increases with the degree of malignancy while Bcl-2
expression decreases as in the recent study (17).

It is the most common chromosomal translocation in
human Iymphoid tissue tumors (8).

1- In ductus cells of all exocrine glands (pancreas, etc.)
2- In proliferating cells
keratinocytes, etc.)

and

stem

cells

(basal

3- In epithelial cells that react to hormonal stimulus
(breast endometrium, prostate tissues) (7).
This protooncogene, which is expressed in the normal
cell, is also shown frequently in Iymphoma, endometrial
carcinoma and prostate carcinoma studies (7,8).
Prostate adenocarcinomas, which have Bcl-2
expression, react better to treatment than non-Hodgkin‘s
Iymphomas which do not have Bcl-2 expression, which in
turn react better to treatment than non-Hodgkin’s
Iymphomas which have Bcl-2 expression (4).
Synovial sarcoma has 100% Bcl-2 expression while
leiomyosarcoma
has
no
Bcl-2
expression
immunohistochemically in tissues (9).
Rajkumar et al. studied Bcl-2 and P53 expression as
immunohistochemical techniques in 40 cases. Bcl-2 was

McCluggue et al. studied P53 and Bcl-2 protein in
non-neoplastic and neoplastic cases. They found P53
expression less frequently in non-neoplastic tissues while
Bcl-2 expression was higher in non-neoplastic cases (18).
Cooper et al. attempted to show Bcl-2 protein
expression in HPV positive cervical intraepithelial
neoplasias, but they could find no relationship between
HPV positivity and Bcl-2 low-grade and high-grade CINs
(19,20).
We found significantly reduced Bcl-2 rates related
with increased grade in our study (general staining 44%).
In the literature there are some studies supporting our
results related with this correlation. However, we found
no statistically significant relationship between stage and
Bcl-2 expression. We observed the highest staining
percentage in stage 1 cases, which were more numerous
403
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(relatively higher positively). There are numerous studies
indicating that Bcl-2 is a good prognostic parameter after
radiation therapy, and some of them support the idea
that it is a strong parameter without any relationship
with radiotherapy. And of course there are reports
stating just the opposite.
In the literature we found no reports on that subject
that included age or lymph node invasion.
We found no significant relationship between the
staining intensity, stage and grade, or between lymph
node invasion, vascular invasion, necrosis, age and Bcl-2,
which are the other prognostic parameters.
Some of these features correlated to some reports in

the literature. We found no significant relationship
between Bcl-2 and the other prognostic parameters, but
Bcl-2 could be used as a marker for blocking wellprogrammed cell death in low-grade cases. We consider
that more cases could be studied, the age range could be
narrowed and an equal number of cases could be chosen
to evaluate the relationship more accurately and
specifically.
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